Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations

INTRODUCTION: MET exon 14 skipping in patients with advanced non-small cell lung cancer (aNSCLC), can be targeted with MET inhibitors including tepotinib, capmatinib, savolitinib, and crizotinib. Matching-adjusted indirect comparison (MAIC) methodology was used to compare outcomes data between agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, Paul K., Pfeiffer, Boris M., Vioix, Helene, Garcia, Andrea, Postma, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239936/
https://www.ncbi.nlm.nih.gov/pubmed/35543963
http://dx.doi.org/10.1007/s12325-022-02163-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239936/
https://www.ncbi.nlm.nih.gov/pubmed/35543963
http://dx.doi.org/10.1007/s12325-022-02163-9

Ejemplares similares